Ensysce Biosciences, Inc. — Form 8-K
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
Ensysce completed acquisition of Cy Biopharma in August 2026, adding CY200 (psilocybin-based candidate for Complex Regional Pain Syndrome with FDA Orphan Drug Designation) as lead asset. Company submitted CY200 Phase 2a protocol to UK MHRA in September 2026; MHRA requested additional information on November 6, 2026. Cash position increased from $4.3M (Dec 2025) to $29.7M (Sept 2026), primarily via $19.6M Series C private placement proceeds and $11.4M cash acquired from Cy Biopharma; recorded $79.9M non-cash IPR&D charge resulting in $82.3M net loss for Q3 2026.
Why this rating
Transformational acquisition for micro-cap ($5.3M market value) adds lead clinical asset and cash runway. However, regulatory delay (MHRA information request) and $79.9M non-cash charge create near-term headwinds offsetting strategic value.
Price action (we called it neutral)
before filing · preread $0.39 ▼ 13.18% | at our read · unknown $0.45 | +10 min · unknown $0.39 ▼ 12.56% | +30 min · unknown $0.42 ▼ 6.50% | +1 hr · unknown $0.41 ▼ 7.00% | +4 hrs · unknown $0.41 ▼ 8.05% |
The stock had already moved +15.19% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.